Cargando…
Cost-effectiveness of antiplatelet drugs after percutaneous coronary intervention
AIMS: Clopidogrel has, for long time, been accepted as the standard treatment for patients who have undergone a percutaneous coronary intervention (PCI). The introduction of prasugrel—and more recently, ticagrelor—has introduced a decision-making problem for clinicians and governments worldwide: to...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862019/ https://www.ncbi.nlm.nih.gov/pubmed/29474586 http://dx.doi.org/10.1093/ehjqcco/qcv023 |